Creatine synthesis and transport during rat embryogenesis: Spatiotemporal expression of AGAT, GAMT and CT1 by Braissant, Olivier et al.
BioMed  Central
Page 1 of 16
(page number not for citation purposes)
BMC Developmental Biology
Open Access Research article
Creatine synthesis and transport during rat embryogenesis: 
Spatiotemporal expression of AGAT, GAMT and CT1
Olivier Braissant*1, Hugues Henry1, Anne-Marie Villard1, Oliver Speer2,3, 
Theo Wallimann2 and Claude Bachmann1
Address: 1Clinical Chemistry Laboratory, University Hospital, CH-1011 Lausanne, Switzerland, 2Institute of Cell Biology, Swiss Federal Institute 
of Technology, CH-8093 Zürich, Switzerland and 3Institute of Molecular Biology, University of Zurich, CH-8057 Zürich, Switzerland
Email: Olivier Braissant* - Olivier.Braissant@chuv.ch; Hugues Henry - Hugues.Henry@chuv.ch; Anne-Marie Villard - Olivier.Braissant@chuv.ch; 
Oliver Speer - Oliver.Speer@molbio.unizh.ch; Theo Wallimann - Theo.Wallimann@cell.biol.ethz.ch; 
Claude Bachmann - Claude.Bachmann@chuv.ch
* Corresponding author    
Abstract
Background: Creatine (Cr) is synthesized by a two-step mechanism involving arginine:glycine
amidinotransferase (AGAT) and guanidinoacetate methyltransferase (GAMT), and is taken up by
cells through a specific Cr transporter, CT1. Recently, genetic defects of this pathway have been
described, that lead to Cr deficiency, neurological symptoms in early infancy and severe
neurodevelopmental delay. To investigate the involvement of Cr synthesis and uptake pathways
during embryonic development, we determined the spatiotemporal expression of AGAT, GAMT
and CT1 during the rat embryogenesis, at the mRNA and protein level.
Results: We show that AGAT and GAMT are expressed in hepatic primordium as soon as 12.5
days, then progressively acquire their adult pattern of expression, with high levels of AGAT in
kidney and pancreas, and high levels of GAMT in liver and pancreas. AGAT and CT1 are prominent
in CNS, skeletal muscles and intestine, where they appear earlier than GAMT. High levels of CT1
are found in epithelia.
Conclusion: Our results suggest that de novo synthesis of Cr by AGAT and GAMT, as well as
cellular Cr uptake by CT1, are essential during embryonic development. This work provides new
clues on how creatine can be provided to developing tissues, and suggests that Cr deficiencies
might induce irreversible damages already in utero, particularly on the nervous system.
Background
Central nervous system (CNS) is the main organ affected
in patients suffering from creatine (Cr) deficiency syn-
dromes due either to AGAT, GAMT or CT1 deficiency [1-
3]. As recently described, these patients present neurolog-
ical symptoms in early infancy and show severe neurode-
velopmental delay [4-6]. All three deficiencies are
characterized by an absence, or a severe decrease, of Cr in
CNS [7,8].
The Cr / phosphocreatine (P-Cr) / creatine kinase (CK)
system is essential for the buffering and transport of high
energy phosphates [9]. Cr is taken up by food, or synthe-
sized endogenously by a two-step mechanism involving
L-arginine:glycine amidinotransferase (AGAT) and S-ade-
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nosyl-L-methionine:N-guanidinoacetate methyltrans-
ferase (GAMT). Cr is taken up by cells through CT1, a
specific Cr transporter belonging to the Na+-dependent
neurotransmitter transporter family. In adult mammals,
AGAT is predominantly expressed in kidney and pancreas,
and GAMT is mainly localized in liver and pancreas. In
addition, both enzymes are also expressed in various
other tissues, albeit at lower levels. The highest expression
of CT1 is found in kidney, heart and skeletal muscle (see
[10] and references therein). Cr synthesis has been
observed in CNS [11]. AGAT and GAMT mRNAs have
been revealed in neurons, astrocytes and oligodendro-
cytes [12,13]. By contrast, CT1 has been found in neurons,
oligodendrocytes and microcapillary endothelial cells,
but is not detectable in astrocytes [13-18]. Cr plays an
essential role in CNS, where it is involved in Na+-K+-
ATPase activity, neurotransmitter release, maintenance of
membrane potentials, Ca++ homeostasis or restoration of
ion gradients (for a review, see [10]). We have further
shown recently that Cr might be involved in axonal
growth [19]. Cr poorly crosses the blood brain barrier of
rodents [20,21]; high doses of Cr given over a long period
of treatment only partially replenish brain Cr of AGAT
and GAMT deficient patients [7,8]. It has thus been sug-
gested that the postnatal and adult CNS might depend, at
least for a part of its needs, on its own Cr synthesis [13].
This is however in contradiction with the fact that CT1
deficient patients, who should express AGAT and GAMT
correctly in their CNS, are nevertheless depleted in intrac-
erebral Cr stores [22].
Little information is available on AGAT, GAMT and CT1
in embryonic development. AGAT (mRNA) and GAMT
(protein) were found in whole extracts of the developing
mouse embryo [23,24]. CT1 mRNA has been shown in
the E14 rat embryo, in the entire neuraxis as well as in
non-neural tissue [15]. The materno-fetal transport of Cr
has been demonstrated [25,26]. As Cr deficiencies lead to
severe developmental delay, our aim was to investigate at
what time and in which tissues the system for Cr synthesis
and transport is expressed during embryonic develop-
ment. We determined therefore the tissue distribution of
AGAT, GAMT and CT1 gene expression in rat embryos
aged of 12.5, 15.5 and 18.5 days, at mRNA and protein
level using in situ hybridization and immunohistochem-
istry respectively.
Results
The developmental expression of AGAT, GAMT and CT1
genes was analyzed in E12.5, E15.5 and E18.5 rat embryos
at the mRNA and protein levels. For each embryonic stage,
patterns of AGAT, GAMT and CT1 expression were vali-
dated by i) the specificity of anti-AGAT, anti-GAMT and
anti-CT1 antibodies (Figure 1), ii) the specificity of in situ
hybridization probes (Figure 3 and [13]), and iii) the
remarkable coherence between in situ hybridization
(mRNA, blue) and immunohistochemistry (protein, red)
stainings (see Figures 3 and 4 for E12.5, Figures 5 and 6 for
E15.5, Figures 7 and 8 for E18.5). Brain structures
enlarged in Figures 3 to 8 (neocortical epithelium,
choroids plexus) are illustrated in Figure 2 at lower
magnification.
E12.5 rat embryos
AGAT was detected in all parts of the E12.5 central nerv-
ous system (Figure 9; Figures 3A; 4A and 4B). Highest lev-
els were detected in the middle part of somites (Figure 3B)
as well as in the hepatic primordium (Figures 3C; 4C).
AGAT was also detected in the wall of dorsal aorta, but
was not detectable in epidermis and heart (Figure 9).
GAMT at E12.5 was detectable in the hepatic primordium
only (Figures 3G; 4F), with all other tissues being negative
(Figure 10, Figures 3E–F; 4D and 4E).
CT1 was expressed by all parts of the E12.5 CNS (Figure
11; Figures 3I; 4G and 4E). In contrast to AGAT which was
restricted to the central part of somites, CT1 was found
expressed throughout the whole somites (Figure 3J). CT1
was also present in the dorsal aorta and the hepatic
Specificity of the anti-AGAT, anti-GAMT and anti-CT1  antibodies Figure 1
Specificity of the anti-AGAT, anti-GAMT and anti-
CT1 antibodies. Western blot analysis of cell extract from 
rat kidney, by anti-AGAT, anti-GAMT and anti-CT1 antibod-
ies. 10 µg of proteins were loaded in each lane. MM is the 
molecular mass marker.BMC Developmental Biology 2005, 5:9 http://www.biomedcentral.com/1471-213X/5/9
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primordium (Figures 3K; 4I). At E12.5, CT1 was not
detectable in epidermis and heart (Figure 11).
In situ hybridization control sections hybridized with the
respective AGAT, GAMT and CT1 sense probes were nega-
tive (Figure 3D, 3H and 3L).
E15.5 rat embryos
AGAT was expressed in most regions of the E15.5 CNS,
with increased levels detected in isolated cells throughout
the developing brain (Figure 9; Figures 5A; 6A). AGAT was
not detected in choroid plexus (Figure 5B), nor in the dor-
sal root ganglia (Figure 9). High levels of AGAT were
observed in skeletal muscles and primordia of gonads
(Figures 5C; 6B), and AGAT was also detected in caudal
somites (as shown earlier at E12.5, Fig. 3B), liver (Figures
5E; 6D) and pancreas, with, as in CNS, higher levels in iso-
lated cells (Figure 9). At E15.5, AGAT could not be
detected in kidney (Figures 5D; 6C), nor in all the remain-
ing tissues observed (Figure 9).
GAMT could not be detected in most of the E15.5 CNS
(Figures 5F; 6E), with the exception of striatum and pons
(Figure 10). High levels of GAMT were found in liver (Fig-
ures 5J; 6H), and it was also expressed in pancreas. All the
remaining tissues observed were negative for GAMT at
E15.5 (Figure 10).
CT1 was strongly expressed in most of the E15.5 CNS (Fig-
ure 11; Figures 5K; 6I). CT1 was detected in choroid
plexus (Figure 5L). CT1 was observed in skeletal muscles
and caudal somites, as well as in kidney (Figures 5N; 6K),
lung, stomach and intestine epithelial cells (Figure 11).
CT1 could not be detected in gonads (Figures 5M; 6J),
liver (Figures 5O; 6L) and pancreas, nor in all the remain-
ing tissues observed (Figure 11).
E18.5 rat embryos
AGAT mRNA was expressed in most regions of the E18.5
CNS (Figure 9). Interestingly, high levels of AGAT mRNA
were detected in endothelial cells of the developing cere-
bral capillaries (Figure 7A), but was absent from choroid
plexus (Figure 9). A high expression of AGAT, both at the
mRNA and protein levels, was also detected in skeletal
muscle (Figure 7C,D), kidney (Figure 7E,F) and pancreas
(Figure 7I,J), while a lower level of AGAT was found in
liver (Figure 7G,H) and intestine epithelial cells (Figure
7K,L). At E18.5, AGAT could not be detected in epidermis
and dermis, in olfactory epithelium, trachea and lung, nor
in stomach and heart (Figure 9).
GAMT was expressed in neocortex (Figure 7M,N), hippoc-
ampus, striatum, pallidum and spinal cord, but could not
be detected in other structures of the E18.5 brain (Figure
10). GAMT was absent from endothelial cells of cerebral
Neocortex of the rat embryo at E12.5, E15.5 and E18.5 Figure 2
Neocortex of the rat embryo at E12.5, E15.5 and 
E18.5. Hematoxylin staining. A: E12.5. B: E15.5. C: E18.5. 
Neocortical and plexus choroid structures depicted by rec-
tangles in A, B and C are enlarged in Figures 3 A,E,I; 4 B,E,H; 
5 A,B,F,G,K,L; 6 A,E,I; 7 A,B,M,N; and 8 A,B. CP: choroid 
plexus; LV: lateral ventricle; N: neocortex; P: pallidum. Bar : 
200 µm.BMC Developmental Biology 2005, 5:9 http://www.biomedcentral.com/1471-213X/5/9
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Expression of the AGAT, GAMT and CT1 mRNAs in the E12.5 rat embryo Figure 3
Expression of the AGAT, GAMT and CT1 mRNAs in the E12.5 rat embryo. In situ hybridization (mRNA, blue signal) 
experiments performed with antisense probes against AGAT (A-C), GAMT (E-G) and CT1 (I-K) mRNAs, and with the sense 
counterpart probes for AGAT (D), GAMT (H) and CT1 (L). A,E,I and D,H,L: dorsal telencephalic neuroepithelium; B,F,J: 
somites; C,G,K: liver. Bar : 100 µm.BMC Developmental Biology 2005, 5:9 http://www.biomedcentral.com/1471-213X/5/9
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capillaries, as well as from choroid plexus. In peripheral
tissues, the highest expression of GAMT, both at the
mRNA and protein levels, was found in skeletal muscles
(Figure 7O,P) and liver (Figure 7S,T), while it was also
present in pancreas (Figure 7U,V) and intestinal epithelial
cells (Figure 7W,X). GAMT could not be detected in the
E18.5 kidney (Figure 7Q,R), nor in all the remaining tis-
sues observed (Figure 10).
CT1 was highly expressed in most regions of the E18.5
CNS, both at the mRNA and protein levels (Figure 11, Fig-
ure 8A,B). CT1 was absent from endothelial cells of cere-
bral capillaries, but highly expressed in choroid plexus
(Figure 11). Most peripheral tissues expressed CT1 (Figure
11), as illustrated for epidermis and dermis (Figure 8C,D),
kidney (Figure 8E,F) and intestine epithelial cells (Figure
8G,H). However, no signal for CT1 could be detected in
liver and pancreas (Figure 11).
Expression of the AGAT, GAMT and CT1 proteins in the E12.5 rat embryo Figure 4
Expression of the AGAT, GAMT and CT1 proteins in the E12.5 rat embryo. Immunohistochemistry (protein, red 
signal) experiments performed with anti-AGAT (A-C), anti-GAMT (D-F) and anti-CT1 (G-I) antibodies. A,D,G : coronal sec-
tion through hindbrain; B,E,H: dorsal telencephalic neuroepithelium; C,F,I: liver. Bar : A,D,G: 200 µm; B,C,E,F,H,I: 100 µm.BMC Developmental Biology 2005, 5:9 http://www.biomedcentral.com/1471-213X/5/9
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Expression of the AGAT, GAMT and CT1 mRNAs in the E15.5 rat embryo Figure 5
Expression of the AGAT, GAMT and CT1 mRNAs in the E15.5 rat embryo. In situ hybridization (mRNA, blue signal) 
experiments performed with antisense probes against AGAT (A-E), GAMT (F-J) and CT1 (K-O) mRNAs. A,F,K: neocortical 
neuroepithelium; B,G,L: choroid plexus; C,H,M: gonadal primordium; D,I,N: kidney; E,J,O: liver. Bar : 100 µm.BMC Developmental Biology 2005, 5:9 http://www.biomedcentral.com/1471-213X/5/9
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Expression of the AGAT, GAMT and CT1 proteins in the E15.5 rat embryo Figure 6
Expression of the AGAT, GAMT and CT1 proteins in the E15.5 rat embryo. Immunohistochemistry (protein, red 
signal) experiments performed with anti-AGAT (A-D), anti-GAMT (E-H) and anti-CT1 (I-L) antibodies. A,E,I: neocortical 
neuroepithelium; B,F,J: gonadal primordium; C,G,L: kidney; D,H,L: liver. Bar : 100 µm.BMC Developmental Biology 2005, 5:9 http://www.biomedcentral.com/1471-213X/5/9
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Expression of AGAT and GAMT in the E18.5 rat embryo Figure 7
Expression of AGAT and GAMT in the E18.5 rat embryo. In situ hybridization (mRNA, blue signal) and immunohisto-
chemistry (protein, red signal) experiments against AGAT (A-L) and GAMT (M-X). A,B,M,N: neocortical neuroepithelium; 
C,D,O,P: skeletal muscle; E,F,Q,R: kidney; G,H,S,T: liver; I,J,U,V: pancreas; K,L,W,X: intestine. Bar : 100 µm.BMC Developmental Biology 2005, 5:9 http://www.biomedcentral.com/1471-213X/5/9
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Discussion
Creatine in embryonic development
The Cr / P-Cr / CK system plays an essential role in energy
homeostasis during the vertebrate embryonic develop-
ment, with prominent activities in tissues such as develop-
ing CNS and muscles [9]. CK genes are expressed very
early in many structures of the vertebrate embryo [27,28],
whereas Cr concentration between 2 and 4 mmol/kg wet
weight are found in the whole rat fetus, depending on the
developmental stage [29]. In CNS, Cr concentration
between 5 and 8 mmol/kg wet weight have been found in
rat and human fetus, depending on the gestational stage
[29,30]. Parts of the developmental needs for Cr can be
fulfilled by the active transport of Cr from the mother to
the embryo [25,26,31]. GAMT knock-out mice, which
develop biochemical alterations comparable to those
found in human GAMT deficient patients, present an
increase in perinatal mortality [24]. It is not known how-
ever whether alterations in Cr pathways, as found in
AGAT, GAMT or CT1 deficiencies, impairs the develop-
ment of the embryo.
AGAT and GAMT for de novo synthesis of Cr in the embryo
As both substrates arginine (for AGAT) and S-adenosyl-
methionine (for GAMT) are available for most tissues
(including liver, brain and muscle) during the mamma-
lian embryonic development [32-34], our study suggests
that the rat embryo might be able of its own Cr synthesis
as soon as E12.5, in the hepatic primordium which
expresses both AGAT and GAMT. From E12.5 to E18.5,
both enzymes then progressively acquire their expression
pattern found in aduldhood, with AGAT mainly expressed
in kidney and pancreas, and GAMT preferentially
localized in liver and pancreas (see [10] and references
therein). As in adulthood however, many other different
embryonic tissues retain low levels of AGAT and/or
GAMT; we found that skeletal muscles and intestinal
epithelial cells at E18.5 are equipped to synthesize their
own Cr by expressing both AGAT and GAMT. A few
embryonic structures express only AGAT (muscles before
E18.5, regions of CNS, blood vessels) suggesting that they
have to release the intermediate GAA, that has to be trans-
ported to GAMT-expressing cells for Cr synthesis to occur,
as it is generally thought between kidney (AGAT) and liver
(GAMT) in adult mammals. A few embryonic structures
(i.e. somites at E12.5 and E15.5, skeletal muscles at E15.5
and E18.5, gonadal primordium at E15.5) showed a strik-
ing and very high expression of AGAT. This might be
explained by the strong and positive regulation of AGAT,
at the transcriptional level, by thyroid, growth and sex
hormones [26,35,36], which do control the embryonic
development of somites, skeletal muscles and gonads [37-
40].
While this study shows that AGAT is expressed as soon as
E12.5 in the whole CNS parenchyme and increases
towards E18.5, it demonstrates also that GAMT expression
in the developing CNS is delayed, and remains at low lev-
els as compared to AGAT. Adult rat CNS appears to be able
of synthesizing its own Cr by expressing AGAT and GAMT
in most cell types of the brain [13]; in contrast, our work
suggests that independance of CNS for its own Cr
synthesis is probably limited to the end of embryogenesis
Expression of CT1 in the E18.5 rat embryo Figure 8
Expression of CT1 in the E18.5 rat embryo. In situ 
hybridization (mRNA, blue signal) and immunohistochemistry 
(protein, red signal) experiments against CT1. A,B: neocorti-
cal neuroepithelium; C,D: skin; E,F: kidney; G,H: intestine. 
Bar : 100 µm.BMC Developmental Biology 2005, 5:9 http://www.biomedcentral.com/1471-213X/5/9
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Expression of AGAT mRNA in the main tissues of the rat embryo Figure 9
Expression of AGAT mRNA in the main tissues of the rat embryo. i : isolated cells ; - : absent ; ± : barely detectable ; 
+ : moderate expression, ++ : strong expression, +++ : very strong expression. More differentiated structures of older stages 
are connected with the “{“ sign to the younger structure from which they originate.                
AGAT E 12.5  E 15.5  E 18.5 
CNS
Forebrain +
(i)
  Neocortex + +
(i)
Olfactory bulb r +
(i)
  Hippocampal formation r
 Ammon’s horn neuroepithelium  r
 Dentate gyrus neuroepithelium +
(i)
Striatum +
(i) +
Pallidum +
(i) +
  Thalamus +
(i) +
  Hypothalamus +
(i) +
Midbrain +
(i)
Pretectum - +
  Tegmentum +
(i) +
  Colliculi r
(i) +
Hindbrain +
(i)
  Cerebellum +
(i) +
Pons +
(i) +
Medulla +
(i) +
Spinal cord +
(i)
  Ependymal layer +
Mantle layer +
Marginal layer -
Dorsal root ganglia - +
Microcapillary endothelial cells ++
Choroid plexus  - -
Other tissues 
Epidermis - - -
Olfactory epithelium  -
Somites +++ +
Dermis - -
Striated muscles +++ +++
Axial skeleton - r
Dorsal aorta + - -
Heart - - -
Gonads +++ +
Kidney - ++
Liver ++ +
(i) +
Pancreas +
(i) +++
Trachea -
Lung - -
Stomach - -
Intestine (epithelial cells) - +BMC Developmental Biology 2005, 5:9 http://www.biomedcentral.com/1471-213X/5/9
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Expression of GAMT mRNA in the main tissues of the rat embryo Figure 10
Expression of GAMT mRNA in the main tissues of the rat embryo. i : isolated cells ; - : absent ; ± : barely detectable 
; + : moderate expression, ++ : strong expression, +++ : very strong expression. More differentiated structures of older stages 
are connected with the “{“ sign to the younger structure from which they originate.                
GAMT E 12.5  E 15.5  E 18.5 
CNS
Forebrain -
 Neocortex - r
 Olfactory bulb - -
 Hippocampal formation -
 Ammon’s horn neuroepithelium  -
 Dentate gyrus neuroepithelium r
 Striatum r +
 Pallidum - +
 Thalamus - -
 Hypothalamus - -
Midbrain -
 Pretectum - -
 Tegmentum - -
 Colliculi - -
Hindbrain -
 Cerebellum - -
 Pons r -
 Medulla - -
Spinal cord -
 Ependymal layer r
 Mantle layer  +
 Marginal layer -
Dorsal root ganglia - -
Microcapillary endothelial cells -
Choroid plexus  - -
Other tissues 
Epidermis - - -
Olfactory epithelium  -
Somites - -
 Dermis - -
 Striated muscles - ++
 Axial skeleton - -
Dorsal aorta - - -
Heart - - -
Gonads - +
Kidney - -
Liver + ++ +++
Pancreas + +
Trachea -
Lung - -
Stomach - -
Intestine (epithelial cells) - +BMC Developmental Biology 2005, 5:9 http://www.biomedcentral.com/1471-213X/5/9
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Expression of CT1 mRNA in the main tissues of the rat embryo Figure 11
Expression of CT1 mRNA in the main tissues of the rat embryo. i : isolated cells ; - : absent ; ± : barely detectable ; + 
: moderate expression, ++ : strong expression, +++ : very strong expression. More differentiated structures of older stages are 
connected with the “{“ sign to the younger structure from which they originate.
CT1 E 12.5  E 15.5  E 18.5 
CNS
Forebrain +
 Neocortex  +++ ++
 Olfactory bulb +++ ++
 Hippocampal formation +++
 Ammon’s horn neuroepithelium  +
 Dentate gyrus neuroepithelium ++
 Striatum ++ +++
 Pallidum ++ +++
 Thalamus  ++ +
 Hypothalamus  ++ +
Midbrain +
 Pretectum ++ r
 Tegmentum ++ r
 Colliculi +++ r
Hindbrain +
 Cerebellum  ++ +
 Pons  +++ ++
 Medulla  +++ ++
Spinal cord  ++
 Ependymal layer ++
 Mantle layer  ++
 Marginal layer -
Dorsal root ganglia r +
Microcapillary endothelial cells -
Choroid plexus  + ++
Other tissues 
Epidermis - - +
Olfactory epithelium  +
Somites + +
 Dermis - +
 Striated muscles r +
 Axial skeleton - +
Dorsal aorta + - -
Heart - - r
Gonads - +
Kidney r ++
Liver r --
Pancreas - -
Trachea +
Lung + +
Stomach + +
Intestine (epithelial cells) + ++BMC Developmental Biology 2005, 5:9 http://www.biomedcentral.com/1471-213X/5/9
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and restricted to discrete regions of CNS. Thus, the
embryonic brain might depend mainly on extra-CNS sup-
ply of Cr, be it of maternal origin or synthesized in other
tissues of the embryo (see below).
CT1 for the supply of Cr to embryonic tissues
From E12.5 to E18.5, most of the embryonic tissues pro-
gressively express CT1, allowing cellular Cr uptake. Nota-
ble exceptions are liver (apart from a low and transient
expression at E12.5) and pancreas, which express GAMT,
and endothelial cells of brain capillaries (see below).
These results are in accordance with earlier work on the
E14 rat embryo [15]. Highest levels of CT1 are found as
soon as E12.5, in tissues requiring high amounts of Cr,
like somites, skeletal muscles and CNS. In gonads, CT1
and GAMT appeared at E18.5 only, while AGAT was
highly expressed at E15.5 and decreased at E18.5. This is
in accordance with their respective expression in the adult
reproductive tract [12,41]. CT2, a second potential Cr
transporter showing 95% nucleotide identity with the
CT1 coding sequence, has been found expressed in testis
solely, at the RNA level [41]. However, CT2 most probably
represents a pseudogene, as it cannot be fully translated
into a functional protein [42], suggesting that the needs in
Cr of the reproductive tract are fulfilled by CT1, as well as
AGAT and GAMT.
The delayed and low level of GAMT expression during
CNS embryogenesis suggests that the embryonic brain
might depend on extra-CNS supply of Cr. This is sup-
ported by our results on CT1, which is expressed at high
levels in the whole embryonic CNS, with a peak at E15.5.
Interestingly, CT1 is expressed in the choroid plexus of the
rat embryo (E15.5 and E18.5), but not of the adult rat
brain [13]. In contrast, CT1 is absent from endothelial
cells of brain capillaries in the embryo, while these cells
express it in the adult rat CNS [13,20]. As choroid plexus
differentiates earlier than brain capillaries and participates
to early trophic supply for CNS [43,44], one might specu-
late that before angiogenesis occurs in CNS parenchyme,
extra-CNS Cr is supplied from blood to cerebrospinal
fluid through the choroid plexus. Cr would then be avail-
able for the whole embryonic brain through cerebrospinal
fluid circulation [45] and the observed high levels of CT1
in the developing neuroepithelium, particularly in epend-
ymal epithelium along ventricles (see below CT1 in sur-
face epithelia exposed to amniotic fluid). As brain
develops and enlarges, and CNS angiogenesis progresses,
the ratio of exchange surfaces in choroid plexus and CNS
microcapillaries shifts to predominance of brain
microcapillaries [43-45]. Thus, at the end of embryonic
development and then postnatally, Cr supply to the brain
may occur preferentially at microcapillaries, with CT1
being up-regulated in capillary endothelial cells and
down-regulated in choroid plexus, as in adulthood
[13,20]. It should be emphasized however that supply of
Cr from blood to postnatal or adult brain is very likely of
less quantitative importance than intra-cerebral Cr syn-
thesis, as astrocytes around blood brain barrier do not
express CT1 [13].
At E15.5 and E18.5, CT1 was found highly expressed in all
epithelia of the rat embryo being in contact with amniotic
fluid, i.e. epidermis, olfactory epithelium, trachea, lung,
stomach, and intestine. Cr uptake has been confirmed
recently in E16 rat embryo intestine [46]. Amniotic fluid
contains significant amounts of Cr (50 to 100 µM in
human depending on gestational age [47]; 320 µM in rat
[46]). It is produced by amniotic cells (at the surface of
chorion) and the foetus, and is continuously renewed by
oral intake of the foetus and excretion (urine). Amniotic
fluid may thus represent an easy way to supply Cr to many
structures of the embryo, through epithelial expression of
CT1 in embryonic parts where vasculature is not yet fully
developed.
It is known that Cr is also supplied by active transport
from the mother to the embryo, accumulating in the cho-
rioallantoic placenta and yolk sac at concentrations higher
than found in maternal or fetal blood, then diffusing
down its concentration gradient into the fetal circulation
[25,26,31]. Thus previous studies, as well as our data, sug-
gest that materno-fetal transport of Cr and de novo syn-
thesis of Cr in the embryo are both necessary for a normal
development to occur.
In utero consequences of AGAT, GAMT or CT1 deficiencies
Patients suffering of AGAT, GAMT or CT1 deficiency
present neurological symptoms in early infancy and show
severe neurodevelopmental delay [7,22]. AGAT and
GAMT deficiencies can be treated with oral Cr, which
slowly replenishes brain levels of Cr [1,3-5,48-50]. Treat-
ment of CT1 deficient patients with oral Cr does not
replenish their CNS Cr level [51]. Despite developmental
improvement and recovery of AGAT and GAMT deficient
patients treated with Cr, sequelae to brain development
and mental retardation remain [7,8]. For GAMT defi-
ciency, this may be due to the toxicity of the GAA accumu-
lating in CNS. Most patients with AGAT, GAMT or CT1
deficiencies are diagnosed during infancy, and significant
damage to their brain occur postnatally. However, AGAT,
GAMT and CT1 expression patterns during the rat embry-
ogenesis suggests that some of the irreversible damages
observed in Cr deficient patients, lacking either AGAT,
GAMT or CT1, may already occur in utero.
Conclusion
We have shown that AGAT, GAMT and CT1 are expressed
by various tissues throughout the development of the rat
embryo. This study suggests that de novo synthesis of CrBMC Developmental Biology 2005, 5:9 http://www.biomedcentral.com/1471-213X/5/9
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and Cr uptake are important for embryonic development.
This work provides new clues on how creatine can be
provided to developing tissues, and suggests moreover
that irreversible damage observed in Cr deficient patients,
lacking either AGAT, GAMT or CT1, may already occur in
utero.
Methods
Preparation of E12.5, E15.5 and E18.5 rat embryos
All animal procedures were in compliance with the direc-
tives of the Swiss Academy of Medical Science. Sprague-
Dawley pregnant female rats (Charles River Laboratories,
France) were fed a standard chow formula. Embryonic
stages of rat embryos were determined from the appear-
ance of vaginal plug in pregnant females. 2 pregnant
females were used for each embryonic stage (E12.5: 12.5
days of gestation, 7 embryos; E15.5: 15.5 days of gesta-
tion, 5 embryos; E18.5: 18.5 days of gestation, 5
embryos). For each embryonic stage, females were sacri-
ficed by decapitation, and embryos were removed from
uterus, rinsed in diethylpyrocarbonate (DEPC)-treated
PBS and fixed for 15 h at room temperature in 4% para-
formaldehyde in DEPC-treated PBS. Subsequently,
embryos were cryoprotected at 4°C in 12% and 18%
sucrose in DEPC-treated PBS for 18 h and 24 h respec-
tively, then embedded in tissue-freezing medium (Jung,
Nussloch, Germany) and frozen in liquid nitrogen cooled
isopentane. Embryos were stored at -80°C until used for
cryosections.
In situ hybridization and immunohistochemistry
Partial cDNAs of the rat sequences AGAT (nt 182-1314,
Gene Bank accession number U07971), GAMT (nt 131-
734, Gene Bank J03588) and CT1 (nt 901-2544, Gene
Bank NM_01738) were used to synthesize antisense and
sense digoxigenin-labeled AGAT, GAMT and CT1 ribo-
probes as described previously [13]. 12 µm thick cryosec-
tions (Leica CM 1800) were prepared for each embryonic
stage, which were analyzed by a sensitive technique of
non-radioactive in situ hybridization [52]. Briefly, cryo-
sections were postfixed 10 min in 4% paraformaldehyde
in DEPC-treated PBS, washed 2 × 15 min in PBS contain-
ing 0.1% fresh DEPC and equilibrated 15 min in 5 × SSC.
Sections were hybridized (58°C for 40 h in 5 × SSC, 50%
formamide and 40 µg/ml salmon sperm DNA) with the
digoxigenin-labeled antisense and sense riboprobes (400
ng/ml) for rat AGAT, GAMT and CT1. Sections were then
washed (30 min in 2 × SSC at room temperature, 1 h in 2
× SSC at 65°C, 1 h in 0.1 × SSC at 65°C) and stained with
alkaline phosphatase-coupled anti-digoxygenin antibody
(Roche, Basel, Switzerland) using nitroblue tetrazolium
and 5-bromo-4-chloro-3-indolyl-phosphate. The specifi-
city of hybridization was ascertained by the use of sense
probes for AGAT, GAMT and CT1 genes having the same
length, GC content and digoxigenin incorporation as their
antisense counterparts. In each in situ hybridization
experiment, a section hybridized with an antisense probe
was always followed by an adjacent section hybridized
with the corresponding sense control probe. After stain-
ing, sections were dehydrated and mounted (Eukit, O.
Kindler Co, Freiburg, Germany).
AGAT, GAMT and CT1 proteins were detected with rabbit
polyclonal antibodies, that were made through injection
of the following antigenic peptides: AGAT N-terminal
amino acids (aa) 62-77 and C-terminal aa 410-423(Swiss-
Prot, accession number P50442); GAMT aa 27-227(Swiss-
Prot, accession number P10868); and CT1 N-terminal aa
15-29 (SwissProt, accession number P28570). Specific
immunoglobulins against AGAT, GAMT and CT1 were
obtained by peptide affinity chromatography. These anti-
bodies recognize specific bands for AGAT (46 kDa),
GAMT (26 kDa) and CT1 (61 kDa) respectively, by west-
ern blotting experiments (Figure 1). AGAT, GAMT and
CT1 proteins were analyzed by immunohistochemistry
on 8 µm thick cryosections using the 3 polyclonal anti-
bodies described above. Briefly, cryosections were post-
fixed for 1 h in 4%PFA in PBS. Endogenous peroxidase
activities were bleached using 1.5% H2O2 in PBS for 15
min. After blocking 1 h in 1% bovine serum albumin in
PBS, anti-AGAT, anti-GAMT and anti-CT1 antibodies were
incubated for 1 h at room temperature in the same buffer.
Their detection by peroxidase staining was performed
using the Histostain Plus Kit (Zymed Laboratories Inc)
with aminoethyl carbazole and H2O2.
The expression patterns of AGAT, GAMT and CT1 genes
observed during the embryonic development were con-
sidered specific and validated by (i) the excellent correla-
tion, in the multiple embryonic tissues analysed, between
the signals observed at the mRNA level by in situ hybridi-
zation and at the protein level by immunohistochemistry,
(ii) the negative signals observed with the in situ
hybridization sense probes (see Figure 3 and [13]), and
(iii) by the absence of any labelling in immunohisto-
chemical controls without primary antibodies or in pres-
ence of pre-immune serum (data not shown).
Sections were observed and photographed on an Olym-
pus BX50 microscope equipped with a DP-10 digital cam-
era (Olympus Opticals, Japan). Structures were identified
according to [53-55], after staining of sections by hema-
toxylin (see Figure 2). In Figures 9,10 and 11 semi-quan-
titative levels of AGAT, GAMT and CT1 mRNA were
determined based on ISH experiments, as described [56].
Levels of transcripts observed by optical microscopy are
indicated by - and + signs which however do not represent
a strict linear mesure of mRNA.BMC Developmental Biology 2005, 5:9 http://www.biomedcentral.com/1471-213X/5/9
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